RxDoctor Payments Data

Kyung Chu

Adult Health · Belleville, NJNPI 1962724393

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,275 of the $10,616 with a category attached, or 77.9%. It is spread thinly across 58 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,616in general payments, 2019–2025

Across 420 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • TG Therapeutics, Inc.$688
  • Incyte Corporation$613
  • Johnson & Johnson$584
  • plus $5K from 52 others

What the payments were for

  • Speaking & faculty fees$6886%
  • Food & beverage$8,27578%
  • Education$3744%
  • Other$1,28012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,616 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide24$437,478
LenvimaLenvatinib Mesylate15$356,813
CabometyxCabozantinib S-Malate14$339,487
TasignaNilotinib Hcl14$279,320
VenclextaVenetoclax18$270,495
NubeqaDarolutamide18$250,435
NinlaroIxazomib Citrate17$215,347
TagrissoOsimertinib Mesylate12$202,972
Lenalidomide15$190,900
BrukinsaZanubrutinib13$174,185
EliquisApixaban136$112,474
XareltoRivaroxaban19$13,811
Fondaparinux Sodium12$9,824
Ondansetron Hcl92$2,399
Anastrozole81$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$76$437,47824 claims
Eisai Inc.Lenvima$90$356,81315 claims
NovartisTasigna$1,588$279,32014 claims
AbbVieVenclexta$377$270,49518 claims
BayerNubeqa$191$250,43518 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$186$215,34717 claims
AstraZenecaTagrisso$1,291$202,97212 claims
Beigene USA, Inc.Brukinsa$76$174,18513 claims
PfizerEliquis$197$112,474136 claims
Johnson & JohnsonXarelto$584$13,81119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →